Cell Reports Medicine最新文献

{"title":"CD47-blocking antibody confers metabolic benefits against obesity.","authors":"Yajuan Su, Jingyu Sun, Xiaobo Li, Feier Huang, Yunhui Kong, Zian Chen, Jingzhi Zhang, Duran Qin, Xiangyi Chen, Zhaoyue Wang, Yu Pei, Mengting Gong, Kaijiang Yang, Minglu Xu, Yu Dong, Qing He, Zhen-Ning Zhang, Zhejin Sheng, Qiaolin Deng, Hong Wang, Gaowei Wang, Ping Hu, Rongrong Le, Shaorong Gao, Weida Li","doi":"10.1016/j.xcrm.2025.102089","DOIUrl":"10.1016/j.xcrm.2025.102089","url":null,"abstract":"<p><p>CD47-blocking antibody is a well-known potential antibody drug for tumor immunotherapy. However, it is unclear whether CD47-blocking antibody can protect against metabolic disorders. We report that high-fat diet (HFD)-induced obesity increases CD47 expression, while exercise downregulates it in skeletal muscle. Administration of CD47-blocking antibody in mice prevents HFD-induced weight gain and glucose intolerance, enhances exercise capacity, and improves body composition and skeletal muscle mitochondrial function. Mechanistically, the protective effects conferred by CD47-blocking antibody are mediated through activation of AMP-activated protein kinase (AMPK) in skeletal muscle. Consistently, muscle-specific CD47-knockout mice show similar metabolic improvements, indicating a direct muscle-specific role of CD47 in regulating AMPK activation in vivo. Furthermore, the CD47-blocking antibody reduces the phosphorylation of heat shock protein 90α (HSP90α) to activate AMPK in skeletal muscle. In conclusion, CD47-blocking antibody confers metabolic benefits by activating the AMPK pathway in skeletal muscle.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102089"},"PeriodicalIF":11.7,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organoid morphology-guided classification for oral cancer reveals prognosis.","authors":"Mi Rim Lee, Sumin Kang, Jonghyun Lee, Sun-Young Kong, Youngwook Kim, Yu-Sun Lee, Hye Won Shon, Gyeongmin Kang, Jiyoung Lee, Suk Min Youn, Da Woon Kwack, Joo Yong Park, Soung Min Kim, Wonyoung Choi, Jong-Ho Lee, Dongkwan Shin, Ik-Jae Kwon, Sung-Woen Choi, Yun-Hee Kim","doi":"10.1016/j.xcrm.2025.102129","DOIUrl":"10.1016/j.xcrm.2025.102129","url":null,"abstract":"<p><p>Oral cancer is an aggressive malignancy with a survival rate below 50% in advanced stages due to low mutation rates, lack of molecular subtypes, and limited treatment targets. This study presents a pioneering approach to classifying oral cancer subtypes based on the morphology of patient-derived organoids (PDOs) and proposes a therapeutic strategy. We establish 76 cancer and 81 normal PDOs. For cancer PDOs, both manual classification and AI-based scoring are utilized to categorize them into three distinct subtypes: normal-like, dense, and grape-like. These subtypes correlate with unique transcriptomic profiles, genetic mutations, and clinical outcomes, with patients harboring dense and grape-like organoids exhibiting poorer prognoses. Furthermore, drug response assessments of 14 single agents and cisplatin combination therapies identify a synergistic treatment approach for resistant subtypes. This study highlights the potential of integrating morphology-based classification with genomic and transcriptomic analyses to refine oral cancer subtyping and develop effective treatment strategies.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102129"},"PeriodicalIF":11.7,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses.","authors":"Hang Lin, Ryan Case, Kathy Y Wei, Ittai Eres, Benjamin M Alba, Joelle Kaner, Yen-Chi Wu, Tracy M Yamawaki, Mina Mostafavi, Hong Zhou, Hayley Ma, Paolo Manzanillo, Weiwen Deng","doi":"10.1016/j.xcrm.2025.102117","DOIUrl":"10.1016/j.xcrm.2025.102117","url":null,"abstract":"<p><p>T cell engagers (TCEs) are transformational oncology therapies but are limited in use due to the induction of cytokine release syndrome (CRS). In comparison to T cells, natural killer (NK) cells produce fewer cytokines upon activation, leading to the exploration of NK cell engagers (NKCEs). However, why NK cells secrete fewer cytokines, such as tumor necrosis factor (TNF), and how NKCEs perform directly against TCEs remains unclear. Here, we report that relative to T cells, NK cells have reduced trafficking and processing of TNF. Systematic development and benchmarking studies show that NKCEs can be optimized to engage multiple activating receptors and incorporate interleukin (IL)-2, thereby increasing their potency and durability. Furthermore, comparative studies of NKCE, IL-2, and TCE therapy in animal tumor models reveal both common and distinct therapeutic benefits. Our results provide a blueprint for the development of multifunctional NKCEs, which may serve as an alternative to current TCE therapies.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102117"},"PeriodicalIF":11.7,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Restoration of intestinal secondary bile acid synthesis: A potential approach to improve pancreatic β cell function in type 1 diabetes.","authors":"Qing Liu, Yifei Hua, Rongbo He, Liqian Xiang, Shaoqing Li, Ying Zhang, Rourou Chen, Li Qian, Xiaomeng Jiang, Congyi Wang, Yangyang Li, Hao Wu, Yu Liu","doi":"10.1016/j.xcrm.2025.102130","DOIUrl":"10.1016/j.xcrm.2025.102130","url":null,"abstract":"<p><p>This study investigates the roles of gut microbiome and secondary bile acid dysfunctions in type 1 diabetes (T1D) and explores targeted interventions to address them. It finds that T1D is associated with reduced gut microbial diversity and imbalance favoring harmful bacteria over beneficial ones. Additionally, patients with T1D exhibited impaired secondary bile acid metabolism. Interventions aimed at modulating the gut microbiome and metabolites are safe and improve glycemic control, reduce daily insulin dose, and reduce inflammation. These interventions reshape the gut microbiome toward a healthier state and enhance secondary bile acid production. Responders to the interventions show increased levels of beneficial bacteria and secondary bile acids, along with improved C-peptide responses. Overall, these findings suggest that targeted modulation of the gut microbiome and secondary bile acid metabolism could be a promising therapeutic approach for T1D management. The trial is registered at Chinese Clinical Trial Registry (ChiCTR-ONN-17011279).</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102130"},"PeriodicalIF":11.7,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of indocyanine green-guided laparoscopic lymphadenectomy for locally advanced gastric cancer: The CLASS-11 clinical trials.","authors":"Chao-Hui Zheng, Ying-Bo Chen, Wen-Bin Yu, Li-Sheng Cai, Quan Wang, Yi-Hong Sun, Su Yan, Xian-Li He, Ze-Kuan Xu, Guo-Xin Li, Yan-Tao Tian, Chen Li, Bao-Gui Wang, Jia-Fu Ji, Yan-Chang Xu, Qing Zhong, Zhi-Yu Liu, Qi-Yue Chen, Ping Li, Jian-Wei Xie, Yao Liang, Zhi-Min Liu, Hai-Bo Qiu, Meng Wei, Zhi-Bo Yan, Chen-Bin Lv, Qiu-Xian Chen, Shuang Li, Ling-Xiao Zeng, Bo-Wen Huo, Zi-Yu Li, Xiang-Qian Su, Chang-Ming Huang","doi":"10.1016/j.xcrm.2025.102136","DOIUrl":"10.1016/j.xcrm.2025.102136","url":null,"abstract":"<p><p>We report the short-term results of indocyanine green (ICG)-guided laparoscopic lymphadenectomy for gastric cancer (GC). The primary outcome is 3-year disease-free survival. In this analysis, we present short-term secondary outcomes focused on the number of lymph nodes (LNs) retrieved and the diagnostic value of fluorescent status for metastatic LNs, excluding long-term outcomes. A total of 1,006 patients are included in the per-protocol analysis. The mean number of LNs retrieved in the ICG group is significantly higher than that in the non-ICG group. The negative predictive value is 93.9% for nonfluorescent stations, and the sensitivity of ICG for detecting all metastatic LN stations is 91.6%. ICG technology is safe and feasible for laparoscopic lymphadenectomy in GC and can noticeably increase the number of LNs retrieved. Further follow-up is necessary to warrant whether ICG can improve long-term survival of GC. The Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS)-11 trial has been registered at ClinicalTrials.gov as NCT04593615.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":"6 5","pages":"102136"},"PeriodicalIF":11.7,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered baseline immunological state and impaired immune response to SARS-CoV-2 mRNA vaccination in lung transplant recipients.","authors":"Mengyun Hu, Ana Paula B N Oliveira, Zhuoqing Fang, Yupeng Feng, Molly Miranda, Sangeeta Kowli, Prabhu S Arunachalam, Gowri Vasudevan, Harold Sai-Yin Hui, Alba Grifoni, Alessandro Sette, Matthew Litvack, Nadine Rouphael, Mehul S Suthar, Xuhuai Ji, Holden T Maecker, Thomas Hagan, Gundeep Dhillon, Mark R Nicolls, Bali Pulendran","doi":"10.1016/j.xcrm.2025.102050","DOIUrl":"10.1016/j.xcrm.2025.102050","url":null,"abstract":"<p><p>The effectiveness of COVID-19 mRNA vaccines is diminished in organ transplant patients. Using a multi-omics approach, we investigate the immunological state of lung transplant (LTX) recipients at baseline and after SARS-CoV-2 mRNA vaccination compared to healthy controls (HCs). LTX patients exhibit a baseline immune profile resembling severe COVID-19 and sepsis, characterized by elevated pro-inflammatory cytokines (e.g., EN-RAGE [also known as S100A12], interleukin [IL]-6), reduced human leukocyte antigen (HLA)-DR expression on monocytes and dendritic cells, impaired cytokine production, and increased plasma microbial products. Single-cell RNA sequencing identifies an enriched monocyte cluster in LTX patients marked by high S100A family expression and reduced cytokine and antigen presentation genes. Post vaccination, LTX patients show diminished antibody, B cell, and T cell responses, along with blunted innate immune signatures. Integrative analysis links these altered baseline immunological features to impaired vaccine responses. These findings provide critical insights into the immunosuppressed condition of LTX recipients and their reduced vaccine-induced adaptive and innate immune responses.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102050"},"PeriodicalIF":11.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A peek into the pipeline: Expert views on emerging therapies.","authors":"Ilse Dewachter, Günter U Höglinger, Daniel J Drucker, Christine E Brown, Roland Martin, Anne Bernadette Chang, Sanjay Haresh Chotirmall, Xiaolong Qi, Pamela Shaw","doi":"10.1016/j.xcrm.2025.102083","DOIUrl":"https://doi.org/10.1016/j.xcrm.2025.102083","url":null,"abstract":"","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":"6 4","pages":"102083"},"PeriodicalIF":11.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A spatially resolved transcriptome landscape during thyroid cancer progression.","authors":"Tian Liao, Yu Zeng, Weibo Xu, Xiao Shi, Cenkai Shen, Yuxin Du, Meng Zhang, Yan Zhang, Ling Li, Peipei Ding, Weiguo Hu, Zhiheng Huang, Man Him Matrix Fung, Qinghai Ji, Yu Wang, Shengli Li, Wenjun Wei","doi":"10.1016/j.xcrm.2025.102043","DOIUrl":"10.1016/j.xcrm.2025.102043","url":null,"abstract":"<p><p>Tumor microenvironment (TME) remodeling plays a pivotal role in thyroid cancer progression, yet its spatial dynamics remain unclear. In this study, we integrate spatial transcriptomics and single-cell RNA sequencing to map the TME architecture across para-tumor thyroid (PT) tissue, papillary thyroid cancer (PTC), locally advanced PTC (LPTC), and anaplastic thyroid carcinoma (ATC). Our integrative analysis reveals extensive molecular and cellular heterogeneity during thyroid cancer progression, enabling the identification of three distinct thyrocyte meta-clusters, including TG⁺IYG⁺ subpopulation in PT, HLA-DRB1⁺HLA-DRA⁺ subpopulation in early cancerous stages, and APOE⁺APOC1⁺ subpopulation in late-stage progression. We reveal stage-specific tumor leading edge remodeling and establish high-confidence cell-cell interactions, such as COL8A1-ITHB1 in PTC, LAMB2-ITGB4 in LPTC, and SERPINE1-PLAUR in ATC. Notably, both SERPINE1 expression level and SERPINE1⁺ fibroblast abundance correlate with malignant progression and prognosis. These findings provide a spatially resolved framework of TME remodeling, offering insights for thyroid cancer diagnosis and treatment.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102043"},"PeriodicalIF":11.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.","authors":"Ruth Plummer, Mikael H Sodergren, Rose Hodgson, Bríd M Ryan, Nina Raulf, Joanna P Nicholls, Vikash Reebye, Jon Voutila, Laura Sinigaglia, Tim Meyer, David J Pinato, Debashis Sarker, Bristi Basu, Sarah Blagden, Natalie Cook, Thomas R Jeffrey Evans, Jeffrey Yachnin, Cheng E Chee, Daneng Li, Anthony El-Khoueiry, Maria Diab, Kai-Wen Huang, Madhava Pai, Duncan Spalding, Thomas Talbot, Marcus S Noel, Bridget Keenan, Devalingam Mahalingam, Min-Sun Song, Mélanie Grosso, Denis Arnaud, Aurelie Auguste, Dimitris Zacharoulis, Jan Storkholm, Iain McNeish, Robert Habib, John J Rossi, Nagy A Habib","doi":"10.1016/j.xcrm.2025.102041","DOIUrl":"10.1016/j.xcrm.2025.102041","url":null,"abstract":"<p><p>Many patients with cancer do not benefit from currently approved immune checkpoint inhibitors (ICIs), suggesting that additional immunomodulation of the immunosuppressive tumor microenvironment (TME) is required. MTL-CCAAT enhancer-binding protein alpha (CEBPA) specifically upregulates the expression of the master myeloid transcription factor, CEBPA, relieving myeloid-driven immunosuppression. Here, we report the safety, tolerability, pharmacokinetics, and efficacy of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumors that typically show ICI resistance. Multimodal exploratory analyses of paired patient biopsies demonstrate biological changes associated with the combination treatment of MTL-CEBPA and pembrolizumab, including increased infiltration of T cell and antigen-presenting cells supporting conversion from an immune-desert toward a more immune-inflamed TME. Patients with disease stabilization demonstrate reductions in immunosuppressive myeloid cells post treatment. Collectively, these data support a role for MTL-CEBPA in reducing immunosuppression in the TME. This study was registered at ClinicalTrials.gov (NCT04105335).</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102041"},"PeriodicalIF":11.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer.","authors":"Shumei Chia, Justine Jia Wen Seow, Rafael Peres da Silva, Chayaporn Suphavilai, Niranjan Shirgaonkar, Maki Murata-Hori, Xiaoqian Zhang, Elena Yaqing Yong, Jiajia Pan, Matan Thangavelu Thangavelu, Giridharan Periyasamy, Aixin Yap, Padmaja Anand, Daniel Muliaditan, Yun Shen Chan, Wang Siyu, Chua Wei Yong, Nguyen Hong, Gao Ran, Ngak Leng Sim, Yu Amanda Guo, Andrea Xin Yi Teh, Clarinda Chua Wei Ling, Emile Kwong Wei Tan, Fu Wan Pei Cherylin, Meihuan Chang, Shuting Han, Isaac Seow-En, Lionel Raphael Chen Hui, Anna Hwee Hsia Gan, Choon Kong Yap, Huck Hui Ng, Anders Jacobsen Skanderup, Vitoon Chinswangwatanakul, Woramin Riansuwan, Atthaphorn Trakarnsanga, Manop Pithukpakorn, Pariyada Tanjak, Amphun Chaiboonchoe, Daye Park, Dong Keon Kim, Narayanan Gopalakrishna Iyer, Petros Tsantoulis, Sabine Tejpar, Jung Eun Kim, Tae Il Kim, Somponnat Sampattavanich, Iain Beehuat Tan, Niranjan Nagarajan, Ramanuj DasGupta","doi":"10.1016/j.xcrm.2025.102053","DOIUrl":"10.1016/j.xcrm.2025.102053","url":null,"abstract":"<p><p>Application of machine learning (ML) on cancer-specific pharmacogenomic datasets shows immense promise for identifying predictive response biomarkers to enable personalized treatment. We introduce CAN-Scan, a precision oncology platform, which applies ML on next-generation pharmacogenomic datasets generated from a freeze-viable biobank of patient-derived primary cell lines (PDCs). These PDCs are screened against 84 Food and Drug Administration (FDA)-approved drugs at clinically relevant doses (C_max), focusing on colorectal cancer (CRC) as a model system. CAN-Scan uncovers prognostic biomarkers and alternative treatment strategies, particularly for patients unresponsive to first-line chemotherapy. Specifically, it identifies gene expression signatures linked to resistance against 5-fluorouracil (5-FU)-based drugs and a focal copy-number gain on chromosome 7q, harboring critical resistance-associated genes. CAN-Scan-derived response signatures accurately predict clinical outcomes across four independent, ethnically diverse CRC cohorts. Notably, drug-specific ML models reveal regorafenib and vemurafenib as alternative treatments for BRAF-expressing, 5-FU-insensitive CRC. Altogether, this approach demonstrates significant potential in improving biomarker discovery and guiding personalized treatments.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":" ","pages":"102053"},"PeriodicalIF":11.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12047494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}